Shelf-stable Growth The CAM360 AmnioGraft shelf-stable amniotic membrane demonstrates demand for ready-to-use ocular surface solutions. Target sales opportunities include eye clinics, hospitals, and eye banks needing easily deployable grafts, with cross-sell potential alongside existing regenerative products.

Channel Partnerships Strategic relationships like LifeLink Tissue Bank show appetite for partnerships that streamline tissue-based product supply. Expand outreach to eye banks, surgical centers, and ophthalmology distributors to accelerate distribution of amniotic membrane products and wound-care offerings in ocular care.

Credible Positioning Recognition as a top workplace and Fortune Best Workplaces can enhance procurement credibility with hospital systems prioritizing supplier stability and clinician-aligned cultures; leverage in RFPs and large account campaigns to differentiate BioTissue from smaller competitors.

Clinical Leadership BioTissue's focus on preserving native tissue with cytokines and growth factors positions it as a premier partner for clinics treating keratitis, recurrent corneal erosions, CCH, pterygium, and dry eye; opportunities for clinical education programs, outcomes data collaborations, and expanded adoption of regenerative membranes.

Strategic Refocus The January 2026 sale of surgical and wound care assets to BioStem signals a focused ocular-surface strategy; explore co-marketing or licensing opportunities with BioStem for joint go-to-market in ocular wound healing, and leverage this focus to pursue targeted distributors and hospital systems that prioritize specialized eye-care membranes.